AveXis (NASDAQ:AVXS) received a $132.00 price target from research analysts at Citigroup in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 29.31% from the company’s current price.
Several other equities analysts also recently issued reports on the stock. Canaccord Genuity set a $110.00 price objective on shares of AveXis and gave the company a “hold” rating in a report on Wednesday, December 20th. BidaskClub raised shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. ValuEngine downgraded shares of AveXis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Bank of America decreased their price target on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Finally, Royal Bank of Canada raised their price target on shares of AveXis from $92.00 to $97.00 and gave the stock a “sector perform” rating in a research note on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. AveXis presently has an average rating of “Buy” and an average price target of $111.94.
AveXis (NASDAQ:AVXS) opened at $102.08 on Friday. AveXis has a twelve month low of $50.56 and a twelve month high of $116.15.
In related news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $101.23, for a total transaction of $1,518,450.00. Following the completion of the sale, the insider now directly owns 1,841,019 shares in the company, valued at $186,366,353.37. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 67,340 shares of company stock valued at $6,840,745. 18.60% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in AVXS. Janus Henderson Group PLC acquired a new stake in AveXis during the second quarter worth about $55,439,000. BlackRock Inc. increased its position in AveXis by 34.7% during the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock worth $189,069,000 after purchasing an additional 592,843 shares during the last quarter. Alliancebernstein L.P. increased its position in AveXis by 4,448.8% during the second quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock worth $46,418,000 after purchasing an additional 552,546 shares during the last quarter. FMR LLC increased its position in AveXis by 13.1% during the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock worth $386,598,000 after purchasing an additional 544,475 shares during the last quarter. Finally, State Street Corp increased its position in AveXis by 104.2% during the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock worth $82,163,000 after purchasing an additional 510,189 shares during the last quarter. Hedge funds and other institutional investors own 92.88% of the company’s stock.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
